Biotech & Life Sciences
TempraMed Posts Record July Sales, Then Announces a CenterWell Pharmacy Deal
The contract is dated August 25. TempraMed announced it on September 23, in a release whose news section runs a single sentence. The company on the other side of that sentence is CenterWell Pharmacy, the pharmacy services brand of Humana. CenterWell Pharmacy Agreement Dated August 25, Announced September 23 TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB:…
Longeveron’s HLHS Trial Misses Primary Endpoint, Reviews Options
A trial run in China just handed Cue Biopharma a stock chart that spiked more than 40% before giving almost all of it back in the same session. Longeveron’s pediatric heart trial met the opposite fate, missing its main goal just days after the company finally cleared a Nasdaq compliance deadline it had spent a…
Inside NurExone’s Push Into Eye and Skin Applications for Its Exosome Platform
NurExone’s exosomes are good at finding damaged tissue. Getting them past the skin’s outer barrier without breaking apart along the way is a separate problem entirely. This week the company partnered with an Israeli device maker that already has an FDA-cleared answer to exactly that problem, the same week its shareholders quietly handed the board…
Tenon Medical Surges on Debt Repayment, Negative Equity Remains
A $5 million debt payment doubled Tenon Medical’s stock price in two days. The company had negative equity going into that payment. AEON Biopharma spent the same stretch adding another data point to a multi-year case that its botulinum toxin candidate matches BOTOX at the molecular level. Neither story ends with an approved product yet,…
Apptly’s OTCQB Listing Follows a Fresh FDA-Approved Imaging Partnership
Apptly Health Technologies signed a partnership with the maker of the only FDA-approved breast CT system on Tuesday. Two days later, on Wednesday, the company’s stock became tradable to a much larger pool of US investors for the first time. The timing wasn’t a coincidence so much as a pattern; it’s roughly the pace the…
Biotech Sector Snapshot: Trial Failure Meets a Rally
One failed trial erased more than a billion dollars from a single biotech’s market value this week. The sector it trades in barely noticed. Both of those facts are true at the same time, and untangling why is more useful than picking a single winner to write about. The Rally’s Math: XBI Up 36% Even…
Apptly’s OTCQB Listing Follows a Fresh FDA-Approved Imaging Partnership
Apptly Health Technologies signed a partnership with the maker of the only FDA-approved breast CT system on Tuesday. Two days later, on Wednesday, the company’s stock became tradable to a much larger pool of US investors for the first time. The timing wasn’t a coincidence so much as a pattern; it’s roughly the pace the…
RenovoRx Hits 52-Week High as Revenue and Trial News Align
RenovoRx spent August checking boxes most microcap biotechs take years to check. A pivotal trial finished enrolling. Quarterly revenue kept climbing. A Nasdaq compliance problem got resolved. By month’s end, the stock was sitting at a 52-week high. RenovoRx Hits 52-Week High as Revenue Growth and Trial Enrollment Both Deliver RenovoRx (Nasdaq: RNXT) shares rose…
Capricor Buys More Time on Deramiocel as an Investor Pushes for Board Change
Capricor’s FDA deadline came and went last Saturday with no announcement. Two days later, the company said the agency had granted a three-month extension instead of a decision. The same week, an activist investor sent Capricor’s other shareholders a letter demanding a board shake-up, timed to land in the middle of the company’s most consequential…
Capricor Gains 11% as FDA Pushes Deramiocel Decision to Nov
A three-month delay is not usually something a stock rallies on. Capricor Therapeutics gained 11% anyway. The company’s Duchenne muscular dystrophy therapy just got a longer FDA review instead of a decision, and investors treated the extra scrutiny as a sign the door stayed open rather than a rejection in slow motion. Capricor Gains 11%…
